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Abstract
Naturally occurring native peptides provide important information about physiological states of an organism and
its changes in disease conditions but protocols and methods for assessing their abundance are not well-
developed. In this paper, we describe a simple procedure for the quantification of non-tryptic peptides in body
fluids. The workflow includes an enrichment step followed by two-dimensional fractionation of native peptides and
MS/MS data management facilitating the design and validation of LC- MRM MS assays. The added value of the
workflow is demonstrated in the development of a triplex LC-MRM MS assay used for quantification of peptides
potentially associated with the progression of liver disease to hepatocellular carcinoma.
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Background
Proteolysis is an important but perhaps the most over-
looked eukaryotic post-translational modification. The
biology of neuropeptides [1], peptide hormones [2,3], and
unusual proteolytically derived signaling molecules [4,5]
stimulates interest in the establishment of appropriate ana-
lytical workflows. Mass spectrometry is one of the most
useful methods for the analysis of complex peptide mix-
tures. Proteomic assays typically utilize sequence-specific
proteases to characterize the components of complex pro-
tein mixtures [6] but the methods for analysis of naturally
occurring peptides, without a proteolytic step, are less
developed. Applications of mass spectrometry to the study
of peptides in various body fluids including cerebrospinal
fluid [7], urine [8], synovial fluid [9], saliva [10] and of
course serum and plasma [11,12] have been described. A
universally useful method for the preparation of the pep-
tides for analysis has not yet emerged and context-specific
optimization is typically required. The reported methods
include ultrafiltration [13], precipitation by organic sol-
vents [14], solid phase extraction [15], size-exclusion chro-
matography [11], differential solubilization method [16],
and nanoparticle trapping technology [17]. Even methods
as simple as direct MALDI-TOF analysis of a complex
mixture in a body fluids were used successfully [12] with
the benefit of high-throughput, minimal preparative losses
of analytes, and minimal sample requirements. Indeed,
MALDI- or SELDI-TOF based analyses are most likely the
richest source of information about native peptides. On
the other hand, these methods suffer from inherent quan-
titative limitations [15,18]. The original semi quantitative
screens are therefore followed by the development of iso-
tope dilution kinetic assays [19] and, most recently, multi-
ple reaction monitoring (MRM) LC-MS/MS quantification
of target peptides [20].
MRM has emerged as an LC-MS alternative to anti-
body based assays for accurate protein quantification
[21]. This targeted technology for monitoring of select
proteins in complex matrices exploits the sensitivity and
selectivity of triple quadrupole mass spectrometers. Spe-
cific combinations of precursor m/z and its fragments
(called transitions) are monitored with linear quantifica-
tion across several orders of magnitude. Perhaps the
most valuable feature of the assays is the ability to mul-
tiplex hundreds of analytes [22]. The design and valida-
tion of new MRM assays, however, is labor and cost
intensive if information about the fragmentation of the
peptides of interest is not available. For protein
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stored in PeptideAtlas may be exploited [23]. PeptideA-
tlas lists peptides most frequently observed in proteomic
studies and their most abundant fragments. Unfortu-
nately, such an information-rich database is not available
for native peptides and minimal data applicable to ESI
ionization are publically available. This substantially
increases the number of potential transitions that must
be considered in assay design, to account for multiple
precursor charge states, the high number of potential
fragments, and their different charge states.
Our overall goal was to develop a workflow leading
from standardized preparation of serum samples,
through data management facilitating the design of
MRM quantification, to the validation in a clinically
applicable assay. We have therefore developed and char-
acterized a simple method that efficiently inhibits pro-
teolytic processes in body fluids, with sufficient peptide
recovery for LC-MRM MS quantification. To facilitate
the design of the MRM assays, we established a Skyline
[24] library of MS/MS spectra of native serum peptides.
To our best knowledge, this is the first attempt to use
2D-HPLC ESI-MS/MS to build a MS/MS library of
native peptides in order to facilitate the design of quan-
titative MRM assays. As a proof-of-concept, the library
was applied to the MRM assay development for three
peptides with diagnostic potential in liver cirrhosis and
hepatocellular cancer [25-27]. This workflow is not spe-
cific to hepatocellular cancer, and is expected to facili-
tate the development of quantitative LC-MS-MRM
assays of native peptides in other studies as well. Speci-
fic experimental endpoints may require different pre-
parative steps but we believe that the establishment of a
publically available library of MS/MS spectra will facili-
tate rapid screening of target analytes in clinically rele-
vant samples. This is expected to improve the ability of
researchers to validate previously suggested or newly
discovered biomarker candidates.
Results and Discussion
Quantification of peptides in biological samples is of
general interest [2,5,11]. The mass spectrometric MRM
quantification of peptides has become a viable alterna-
tive to the traditional ELISA assays [28,29]. MRM quan-
tification is an appealing alternative particularly for
multiplex assays of proteolytically modified peptides,
such as the native peptides discussed in this article. A
d i s c u s s i o no ft h eb i o l o g yo ft h en a t i v ep e p t i d e si s
beyond the scope of this paper; we do not make any
claims as to physiological or diagnostic relevance of the
peptides analyzed here. We focus on the presentation of
a general method for peptide extraction from body
fluids and on the generation of native peptide MS/MS
library to facilitate the design of quantitative assays for
the exploration of the biology of native peptides. It is
hard to imagine that a specific quantitative ELISA assay
for each of the peptides can be developed; LC-MRM
MS is an inviting alternative in this context [28]. We
have therefore first optimized a denaturing ultrafiltration
method for stabilization and extraction of the native
peptides in body fluids and then used the protocol to
create a library of MS/MS spectra that helped us opti-
mize efficiently the MRM quantification of three native
peptides.
Effect of different solvents on peptide yield
Achieving stability of peptides in body fluids is a com-
mon quantitative challenge [28,30]. We have shown by
two independent methods that the yield of peptides
from serum stabilized with 6 M guanidine hydrochloride
(guanidine HCl; G-HCl in figures) is higher than the
yield from serum stabilized with acetonitrile (AcN) (Fig-
ure 1). Dilution with water led to about 3× lower yield
compared to guanidine-HCl while AcN at 20% partially
improved recovery. This is likely related to proteolytic
degradation of the peptides and (non)specific adsorption
of native peptides on surfaces and carrier proteins. The
highly denaturing guanidine HCl conditions inactivate
trypsin and other proteases and disrupt nonspecific
binding of peptides to carrier proteins such as albumin
[31] and high-density lipoprotein [32]. Samples contain-
ing guanidine HCl can be efficiently desalted by C18
solid phase extraction or directly during well-designed
reverse phase chromatography. The results suggest that
stabilization of the peptides with 6 M guanidine HCl is
more efficient than 20% AcN.
The ultrafiltration membranes are an efficient enrich-
ment device in combination with the guanidine HCl
denaturation, but it must be pointed out that the cutoff
values are not precise; loss of some peptides below the
cutoff and leakage of proteins with mass above the cut-
off seems unavoidable. The membranes were designed
to retain polypeptides above the cutoff; but the recovery
of peptides from the filtrates must be verified and opti-
mized. We find that both saturation of non-specific
Figure 1 BCA (A) and HPLC-UV (B) quantification of peptides in
the ultrafiltrates prepared in water, 20% Acetonitrile, or 6 M
guanidine HCl. Each sample was prepared in triplicate.
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albumin (BSA) and the guanidine HCl denaturing condi-
tions improve recovery. Other studies have shown that
the filtrate may be contaminated by proteins above the
mass cut-off of the filters [33]. We have therefore frac-
tionated the ultrafiltrates by HPLC, using a ProSwift
RP-1S 4.6 × 50 mm monolithic column. Native peptides
were detected using MALDI-TOF MS only in early frac-
tions. A standard in-solution tryptic digestion of the
later eluting fractions followed by LC-MS/MS identified
tryptic peptides of albumin, alpha-2-HS glycoprotein,
apolipoprotein A-I and apopolipoprotein C-III. These
contaminants eluted from the reverse phase monolith at
higher AcN concentrations. Consequently, we used 35%
instead of initial 80% AcN for elution of peptides from
the RP SPE cartridges to further enrich low molecular
weight peptides. The chromatograms of ultrafiltrates
eluted with 35% AcN show the removal of the large
polypeptide fraction without affecting the recovery of
low molecular weight peptides. SDS Bis-Tris gel electro-
phoresis of proteins further confirmed that 35% organic
SPE elution solvent helped with removal of residual pro-
teins whose bands were detected in the ultrafiltrates
eluted from SPE in 80% AcN. This was accompanied by
a decrease of the ultrafiltrate polypeptide concentration
measured by BCA assay (Figure 2). The large polypep-
tides at this low concentration do not directly interfere
with the LC-MS analysis of native peptides but can lead
to overestimates of the peptide concentration.
Test of denaturing conditions in a BSA/trypsin model and
in serum
To evaluate the inhibition of proteolysis by the guani-
dine HCl, we used a BSA trypsin digest model. MALDI-
TOF MS analysis demonstrates that guanidine HCl at a
6 mol/l concentration stops the catalytic activity of tryp-
sin (Figure 3). The denaturing activity of 20% AcN, used
for this purpose in other studies, including ours [13,14],
is significantly lower, as trypsin clearly retains activity
under these conditions. The concentration of AcN can-
not be increased in this setting because higher concen-
trations are not compatible with the ultrafiltration
membrane. The MALDI-TOF results were confirmed by
HPLC-UV chromatograms; again, the tryptic activity is
similar in the water solvent control and with the addi-
tion of 20% AcN (Figure 3b). Proteolysis is inhibited
with 6 M guanidine HCl, where the parent protein
remains intact.
To confirm the denaturing efficiency of 6 M guanidine
HCl in serum, we have used heavy analogs of FIBA,
CO3, CO4 (fibrinogen alpha chain, complement C3, and
complement C4) native serum peptides observed in our
previous studies (Figure 4) [25-27].
The heavy peptide analogs were added to serum right
after incubation in either water or guanidine HCl and
the rate of peptide disappearance was evaluated at short
(2 h) and prolonged (overnight) incubation times. The
results show substantial degradation of all the tested
peptides in serum diluted with water. The peptides have
different susceptibility to proteolytic degradation, evi-
denced by the varying rates of degradation in water at
the 2 h incubation time point. Stabilization of the pep-
tides in serum requires denaturing conditions. The use
of 6 M guanidine HCl stabilizes the peptides quite effec-
tively even at the overnight incubation time. The stabili-
zation of peptides in other body fluids still remains to
be verified, but there is no reason to believe that proteo-
lysis would not be inhibited to a similar degree; the 6 M
guanidine HCl should provide effective starting condi-
tions for the optimization of native peptide stabilization
and recovery. We suggest that quantification of the
native peptides in serum and other body fluids under
standardized and validated analytical methods will clarify
the controversies reported in the literature.
Recovery of peptides of interest after denaturing
ultrafiltration
Besides the total peptide yield we examined the recovery
of three peptides of interest after denaturing ultrafiltra-
tion in guanidine HCl. The recovery of CO3 and CO4
peptides was 58% and 54%, FIBA peptide showed
greater than 100% recovery most likely due to its high
concentration in the serum that was used as the matrix.
We thus repeated the experiment with a BSA solution
instead of serum because albumin is the most abundant
serum protein and its solution reasonably mimics the
serum environment. This resulted in a recovery of 78%.
Identification of native serum peptides using 2D LC-MS/
MS and construction of an MS/MS spectral library
The goal of our study was to design effective LC-MRM
MS quantification assays of native peptides. The design
Figure 2 Polypeptide concentration in the ultrafiltrates eluted
with 35% and 80% AcN following C18-SPE desalting. Each
sample was prepared in triplicate.
Lenco et al. Proteome Science 2012, 10:7
http://www.proteomesci.com/content/10/1/7
Page 3 of 12Figure 3 MALDI-TOF (A) and HPLC-UV (B) analysis of tryptic digests of BSA in water, 20% AcN, and 6 M guanidine HCl. The inverted
spectra in panel A represent digests with trypsin compared to an appropriate solvent control. HPLC-UV chromatograms in panel B show peptide
peaks after trypsin digestion in water and 20% AcN and the parent peak for undigested BSA protein in the presence of 6 M guanidine HCl. Each
sample was prepared in triplicate and one representative spectrum or chromatogram is presented
Figure 4 Recovery of three peptides (FIBA, CO3. and CO4) from serum following 2 h and overnight incubations with the addition of 6
M guanidine HCl or water. Each sample was prepared in triplicate.
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greatly simplified when information about the likely
fragments of the peptides is available. Instead of consid-
ering and testing the many possible transitions for each
peptide, we decided to build a MS/MS library of spectra
to facilitate the design process. To this end, we pro-
cessed serum samples using the optimized ultrafiltration
procedure and fractionated the samples by a two dimen-
sional high/low pH RP chromatography for MS/MS ana-
lysis using a QTOF mass spectrometer. The off line high
pH step is orthogonal to the subsequent low pH
nanoLC-MS/MS as described previously and leads to a
significant increase in the number of peptide identifica-
tions [34]. The combined LC-MS/MS analysis of all the
high pH fractions resulted in the identification of 186
protein groups (at ProteinPilot confidence 95%) on the
b a s i so f1 2 , 7 6 2d i s t i n c ti d e n t ified peptides. In order to
further reduce the potential for errors in the spectral
library, we kept only the highest confidence peptide
identifications. After additional filtering of peptide iden-
tifications based on precursor mass-delta, reported post-
translational modification, and score, the false discovery
rate (FDR) of peptides included in the library was esti-
mated as 1.23% at the spectra level, 3.61% at the ion
level, and 4.30% at the peptide level.
Initially, we considered various modified peptides,
including deamidated peptides, identified by ProteinPilot
for the inclusion in the library; however, our analysis
suggests that including these identifications significantly
degrades the FDR of the resulting peptide identification
set without significantly increasing the number of
peptides or ions. The spectra were finally imported into
a custom Skyline library (see Additional file 1) in order
to create a generally available resource [24]. The final
number of precursors imported in the library is 416,
representing 349 unique peptide sequences from 83 pro-
teins (parsimony assignment). Proteins with 10 or more
unique native peptides include fibrinogen alpha chain
(69), inter-alpha-trypsin inhibitor heavy chain H4 (26),
complement C4-A (21), complement C3 (19), fibrinogen
beta chain (15), apolipoprotein A-I (12), serum albumin
(11), prothrombin (10) and zyxin (10).
The peptide fragmentation in the QTOF (QSTAR
Elite, AB Sciex) and 4,000 QTRAP (AB Sciex) mass ana-
lyzers are expected to be similar and we find the frag-
mentation informative for the design of MRM
transitions (Figure 5). The QTOF and QTRAP mass
spectrometers are both manufactured by AB Sciex; dif-
ferences in the peptide fragmentation in instruments
from other manufactures may be more substantial. The
lack of instrument-specific spectra is a significant con-
cern, but long-term, we expect this to be resolved by
sharing of MS/MS spectral information by research
groups. The importance of PeptideAtlas for the design
of MRM assays of tryptic peptides suggests that such as
resource for native peptides should be considered [23].
The benefit of the library is perhaps best summarized
by the following observation. To design MRM assays for
the FIBA, CO3 and CO4 peptides, we have considered
following peptide characteristics: precursor charges: 2, 3,
4; fragments charges: 1, 2; fragment types: y, b; first
fragment - last fragment: 1 to last - 1; m/z from - to:
100-2000. A comprehensive testing of peptide fragments
with these characteristics requires the consideration of
459 transitions for the CO3, CO4 and FIBA peptides.
For tryptic peptides, attention can be focused on y-series
fragments for Q3 filter masses, as these are most likely
to provide sensitive transitions. This is because trypsin
digestion results in peptides with the basic amino acids,
arginine or lysine, at the C-terminus, leading to intense
y-series ions formation under fragmentation. Further-
more, as tryptic peptides are short and usually carry lim-
ited number of basic amino acids, doubly charged
precursor and singly charged fragments can be preferen-
tially selected for MRM assays. Unfortunately, these
heuristic rules cannot be extrapolated to native peptides.
This substantially increases the number of potential
transitions that must be considered and tested. In fact,
for the CO3 peptide SSKITHRIHWESASLL in charge
states +3 and +4, all of the selected transitions were
doubly-charged b-ions. The MS/MS library allows us to
select just five transitions for each precursor, resulting
in the optimization of just 20 transitions. The spectral
library turns the task of thoroughly optimizing 459 tran-
sitions for the quantification of three peptides into the
Figure 5 Intensity of fragment ions of the doubly charged
FIBA peptide in the MS/MS spectrum; the most intense
fragments from the QTOF spectrum correspond to the three
most intense 4000 QTRAP MRM transitions.
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Furthermore, without the library, it is unclear when mul-
tiply charged or b-ion transitions should be considered,
or y-ion transitions removed from consideration. In one
case (SSKITHRIHWESASLL), a Lys residue near the N-
terminus suggests b-ion transitions should be considered,
but for another peptide (NGFKSHALQLNNRQI) with
Lys residue near the N-terminus, the Arg residue near
the C-terminus ensures that y-ion are abundant. For the
peptide DSGEGDFLAEGGGVR, the y6-ion is much less
abundant than y7 and y5 and should perhaps not be used.
MRM analysis
To demonstrate the utility of the optimized workflow
and the MS/MS library, we have designed LC-MRM MS
assays for the quantification of the FIBA, CO3, and CO4
peptides in serum samples. These peptides were chosen
based on our previous screens, which showed differ-
ences in the abundance of these peptides in the serum
of hepatocellular cancer patients when compared to the
serum of chronic liver disease patients and disease free
controls [25,26].
We first selected the five most intense transitions for
each peptide based on the data in the MS/MS library.
Collision energy was optimized for each transition and
the declustering potential was optimized for each pre-
cursor. The three most intense transitions per precursor,
after optimization, were selected for the FIBA and CO4
peptides; for the CO3 peptide, the two most intense
optimized transitions from both triply and quadruply
charged precursors were used (Table 1). We have
further tested the linearity of the response for the
selected transitions, assessed the potential cross-talk
between light and heavy analogues of the peptides, eval-
uated potential background interference, and estimated
the carry-over between chromatographic runs. The
assays were linear over 3.4 orders of magnitude with
limit of quantification 0.8 fmol/μl( F I B A ,C O 4 )a n d4
fmol/μl (CO3) (see). The cross talk was negligible and
the carry-over was less than 1% due to the injection of a
blank (50% trifluoroethanol and AcN) between samples.
We did not observe a shift in normalized peak areas
obtained from spiked heavy labeled peptides or native
peptides in serum when compared to the expected
values. This shows that the quantification is not affected
by background interference. Based on these characteris-
tics, we have adopted these optimized transitions for the
absolute quantification of these peptides in serum sam-
ples. The optimized assays included denaturation of
serum with 6 M guanidine HCl, ultrafiltration, desalting
of the filtrate on the C18 SPE cartridges, and a triplex
LC-MRM MS quantification as described in the meth-
ods. Total run time of the assay was 20 min with the
average retention time of 9.78 min (FIBA), 9.61 min
Table 1 Optimized transitions selected for the quantification of FIBA, CO3, and CO4 peptides and their heavy
analogues
Protein name Peptide sequence Form Precursor m/z Precursor charge Product m/z Product charge Fragmention DP CE
FIBA DSGEGDFLAEGGGVR Light 733.33 2 758.42 1 y8 85 38.3
733.33 2 645.33 1 y7 85 38.3
733.33 2 445.25 1 y5 85 38.3
Heavy 735.84 2 761.43 1 y8 85 38.3
735.84 2 648.34 1 y7 85 38.3
735.84 2 448.26 1 y5 85 38.3
CO3 SSKITHRIHWESASLL Light 622.34 3 810.92 2 b14 80 27.9
622.34 3 867.46 2 b15 80 26.4
Heavy 624.68 3 810.92 2 b14 80 27.9
624.68 3 870.97 2 b15 80 26.4
Light 467.01 4 767.40 2 b13 70 21.7
467.01 4 810.92 2 b14 70 17.2
Heavy 468.76 4 767.40 2 b13 70 21.7
468.76 4 810.92 2 b14 70 17.2
CO4 NGFKSHALQLNNRQI Light 580.65 3 885.49 1 y7 85 29.6
580.65 3 757.43 1 y6 85 31.1
580.65 3 644.35 1 y5 85 31.1
Heavy 582.99 3 892.51 1 y7 85 29.6
582.99 3 764.45 1 y6 85 31.1
582.99 3 644.35 1 y5 85 31.1
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three peptides (Figure 6).The absolute concentration of
these peptides, as opposed to relative quantification in
our previous studies, were determined in the samples of
healthy donors (n = 8), patients with chronic liver dis-
ease (n = 6) and hepatocellular carcinoma (HCC) (n =
7). The heavy labeled peptide standards were spiked
into the 8 M guanidine HCl solution that was added to
each serum sample as the first step of the sample pre-
paration. This minimizes the error introduced in abso-
lute quantification that might result from differences in
peptide degradation or recovery in the preparative steps.
Kruskal-Wallis test with Dunn’s post test confirmed
significant differences in concentration of FIBA and
CO3 peptides between cancer patients and the healthy
and liver disease control groups
The FIBA and CO3 peptides appear significantly lower
in the cancer patient samples compared to the chronic
liver disease patients and healthy controls as observed in
our previous studies. We did not confirm the increase in
the CO4 peptide observed previously; the concentration
of this peptide is substantially lower and the variation in
measured abundance appears to dominate the magnitude
of the change. It is possible that our previous MALDI-
TOF based analysis was not sufficiently accurate, but we
cannot, however, exclude other explanations like degra-
dation of the peptide in storage. We want to emphasize
that we are not making claims of biological importance
or disease classification in this paper; we are presenting a
workflow for native peptide extraction and the use of a
MS/MS library of spectra for facilitating the design of
quantitative MRM assays for native peptides.
Conclusions
Accurate quantification studies of native peptides are
expected to substantially increase our understanding of
their function in biological processes. Mass spectrometry
offers inviting possibilities for their quantification even
in complex biological matrices like body fluids. The
semi-quantitative screens based on relative quantifica-
tion are increasingly being replaced by improved meth-
o d ss u c ha sL C - M R MM Sa s s a y s .I nt h i sp a p e r ,w e
present a workflow for the analysis of native peptides
with emphasis on optimization of the enrichment proto-
col and characterization of the serum peptidome. We
demonstrate the benefits of stabilizing serum samples
with 6 M guanidine HCl as well as the added value of
the workflow in the facilitated development of LC-MRM
MS assay of peptides derived from fibrinogen alpha
chain, complement C3 and complement C4. The publi-
cally available library of MS/MS spectra is expected to
facilitate design of the MRM assays by a wider group of
investigators. The triplex quantitative method has been
evaluated on serum samples of 21 individuals in the
context of the progression of liver disease to hepatocel-
lular carcinoma.
Methods
Material
Native peptides derived from fibrinogen alpha chain,
complement C3 and complement C4 were used in this
study. The peptides and their isotopically labeled analogs
were purchased from the Synthetic Peptide Application
Lab at the University of Pittsburgh (FIBA, DSGEGD-
FLAEGGGVR) or Emory University Michrochemical
Facility (CO3, SSKITHRIHWESASLL and CO4,
NGFKSHALQLNNRQI). The DSGEGDFLAEGGGVR
peptide analog carried one
13C isotope in each glycine
residue, while the SSKITHRIHWESASLL and
NGFKSHALQLNNRQI peptides carried six
13C and one
15N isotopes in a leucine at position 15 and 10, respec-
tively. Guanidine hydrochloride, trifluoroacetic acid,
Figure 6 Quantification of FIBA, CO3, and CO4 peptides in samples of healthy controls (C), chronic liver disease patients (LD), and
hepatocellular cancer patients (HCC).
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tridges, and ammonium bicarbonate were purchased
f r o mS i g m a - A l d r i c h( S t .L o u i s ,M O ) .B C Aa s s a y ,B S A
standard, methyl methanethiosulfonate, and tris(2-carbox-
yethyl) phosphine hydrochloride (TCEP) were purchased
from Pierce (Rockford, Il). Amicon Ultra-0.5 ml ultrafil-
ters with 30 kDa MWCO membrane were from Millipore
(Billerica, MA). Sequencing Grade Modified Trypsin was
obtained from Promega (Madison, WI). Water Optima
LC/MS, acetonitrile Optima LC/MS, and formic acid
(FA) Optima LC/MS were purchased from Fisher Scienti-
fic (Fair Lawn, NJ). Guard column XTerra MS C18, 5
μm, 2.1 × 20 mm, analytical column XTerra MS 3.5 μm
C18 2.1 × 100 mm, trap column nanoACQUITY UPLC 5
μmS y m m e t r yC 1 8 ,1 8 0μm × 20 mm, and nanoAC-
QUITY UPLC column, 1.7 μm BEH C18, 75 μm×1 5 0
mm were obtained from Waters (Milford, MA). Column
ProSwift RP-1S, 4.6 × 50 mm column was purchased
from Dionex (Sunnyvale, CA). PicoTip emitter tips were
from New Objective (Woburn, MA). NuPAGE 10% Bis-
Tris electrophoretic gels, running and sample buffers and
XCell SureLock Mini-Cell were from Invitrogen (Carls-
bad, CA).
Blood collection, processing and serum handling
Samples were collected in agreement with established
IRB protocols. Patients diagnosed with hepatocellular
carcinoma were enrolled at the National Cancer Insti-
tute of Cairo University, Egypt, from 2000 to 2002 as
described previously [27,35]. Individuals free of liver dis-
ease were recruited from the orthopedic department of
Kasr El-Aini Faculty of Medicine at Cairo University
and samples from the patients diagnosed with chronic
liver disease were acquired at the Ain Shams University
Specialized Hospital and the Tropical Medicine
Research Institute, Cairo, Egypt as described [27,35].
Briefly, adults (age 18 and older) previously diagnosed
with HCC and those without a prior history of cancer
were eligible to participate in the study. The presence of
HCC and chronic liver disease was confirmed by pathol-
ogy, cytology, imaging and elevated levels of serum AFP.
Blood samples were collected by a trained phlebotomist
each day at around 10 a.m. and processed within a few
hours according to a standardized protocol. Aliquots of
sera were frozen immediately after collection and stored
at -80°C until the time of analysis.
Preparation of native peptides by denaturing
ultrafiltration
Serum (100 μl) was diluted with water (300 μl), 8 M
guanidine HCl (300 μl, final concentration 6 mol/l), or
AcN (300 μl, final concentration 20%). The Amicon
Ultra-0.5 ml ultrafilters with 30 kDa MWCO membrane
were washed twice with 500 μl of 6 M guanidine HCl at
5.000 × g for 15 min. The remaining wash solution was
removed by converting the filter upside down and spin-
ning at 1.000 × g for 1 min. Samples were filtered at
8.000 × g and 30 min. Peptides were cleaned-up using
C18 SPE cartridges; 3 M Empore C18-SD cartridges
were washed with 0.5 ml of methanol and equilibrated
with 0.5 ml of SPE solvent A (2% AcN, 0.1% trifluoroa-
cetic acid (TFA)). After diluting 80 μl of the ultrafiltrates
with up to 1 ml of the SPE solvent, samples were loaded
onto the cartridges and trapped peptides were washed
with 1 ml of SPE solvent A. Peptides were eluted with
0.4 ml of SPE solvent B (80% AcN, 0.1% TFA or 35%
AcN, 0.1% TFA) directly into a new micro-tube. BCA
assay and a UV-based HPLC assay were used to esti-
mate the peptide yield in the ultrafiltrate. Each sample
was prepared for this purpose in triplicate.
BCA assay
SPE eluates were dried in a vacuum centrifuge and re-
dissolved in 20 μl of 0.2% SDS solution. The BCA assay
was used according to the instruction of manufacturer
with minor modifications. A 5 μl aliquot of each sample
was incubated with a 20 μl of a 50:1 ratio of the kit
reagent A:B at 37°C for 1 h. Absorbance was measured
against a BSA protein standard curve with each sample
measured in triplicate. Samples outside the linear range
were diluted accordingly. Absorbance at 562 nm was
determined using a micro-volume UV-vis spectrophot-
ometer ND-1000 (Thermo-Fisher, Wilmington DE).
UV-based HPLC assay
This assay was used for relative comparison of the pep-
tide yield. Fifty microliters of the ultrafiltrate were
diluted 20× by RP solvent A (2% AcN, 0.05% TFA). For
each replicate, 900 μl was loaded onto the column on
HP 1100 HPLC system (Hewlett Packard, Waldbronn,
Germany); we used a guard-column (XTerra MS C18, 5
μm, 2.1 × 20 mm) heated to 40°C at a flow rate of 1 ml/
min with the peptides eluted by a step increase from 0%
to 70% of RP solvent B (98% AcN, 0.05% TFA) in 0.01
min. The chromatogram was monitored at 214 nm and
a blank chromatogram resulting from the injection of 10
μl of RP solvent A was subtracted. Area of all detected
peaks was summed up as an estimate of peptide quan-
tity. This allowed us to assess the quantity indepen-
dently of any secondary reaction of the peptides
required in the BCA assay.
Recovery of peptides of interest after denaturing
ultrafiltration
Light synthetic peptides FIBA (50 pmol), CO3 (5 pmol)
and CO4 (2 pmol) dissolved in 45 μlo f8Mg u a n i d i n e
HCl were added to 15 μl of serum. The ultrafiltration
was performed as described above. Ultrafiltrate (30 μl)
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pmol), CO3 (2.5 pmol) and CO4 (1 pmol) and desalted
on C18 SPE cartridges as stated above. The concen-
trated SPE eluate (approximately 50 μl) was mixed with
2.5 μl of a matrix solution (3.6 mg of CHCA/ml of 50%
AcN, 0.1% TFA). From this mixture 0.7 μlw a ss p o t t e d
in triplicate on an Opti-TOF MALDI sample plate and
the MS spectra were recorded in relfectron mode on a
4800 MALDI-TOF/TOF mass spectrometer (Applied
Biosystems/MDS Sciex, Foster City, CA). The intensity
of peaks corresponding to m/z of non-labeled and
labeled FIBA, CO3 and CO4 peptides were extracted
and the ratio of light and heavy peptide analogs was cal-
culated. The ratios were compared to ratios obtained
from the direct mixture of light and heavy peptides pre-
pared from the same starting solutions that did not
undergo ultrafiltration. The recovery was calculated as
the change in ratios determinedi ns p i k e du l t r a f i l t r a t e s
of serum and directly in the peptide mixture.
MALDI-TOF and HPLC-UV analysis of the denaturing
conditions in a BSA/trypsin model
Eight microliters of a BSA solution (2.5 μg/μl) was added
either to water, 20% AcN, or 6 M guanidine HCl as
above. BSA was TCEP reduced, blocked by methyl
methanethiosulfonate, and digested with 0.4 μg of trypsin
in 100 mM ammonium bicarbonate buffer, pH 7.5, at 37°
C for 40 h. Instead of the trypsin solution, water was
added as a control. The reaction was stopped with the
addition of 380 μl of the above RP solvent A. The results
were evaluated using MALDI-TOF mass spectrometry
and an HPLC analysis with UV detection. For MALDI
analysis, 30 μl of the sample was desalted on 3 M Empore
C18-SD cartridges using the same procedure as described
above. The SPE eluates were concentrated in a vacuum
centrifuge to approximately 20 μl. MALDI-TOF analysis
was conducted in triplicate as described in the previous
section. For the HPLC-UV detection, 200 μl was loaded
onto a ProSwift RP-1S, 4.6 × 50 mm column. The ther-
mostat was set up at 60°C and the flow rate was 1.8 ml/
min. The gradient was from 0% to 75% B in 6 min. The
chromatogram was monitored at 214 nm.
Test of denaturing potential using three native peptides
in serum
Serum (15 μl) was diluted either with 60 μl of water or
60 μl of 8 M guanidine HCl (final concentration 6 mol/
l). Synthetic peptide standards were added to each
serum sample as follows to achieve comparable detector
response: 187.5 pmol of CO3 peptide and 37.5 pmol of
CO4 peptide. The samples were incubated for two
hours and a second batch of samples was incubated
overnight. After incubation, isotopically labeled peptides
were added to each sample in the following amount: 25
pmol of FIBA, 250 pmol of CO3 and 50 pmol of CO4
which gives initially an approximately 1:1 response
(CO3 and CO4) and 6:1 response (FIBA) with respect to
the light peptide. Negative control samples were pre-
pared in exactly the same way but without the two hour
incubation. Low molecular mass polypeptides including
the added synthetic peptides were enriched by ultrafil-
tration as described above including the C18 SPE car-
tridge cleanup. MALDI-TOF analysis was conducted in
triplicate as described above. The intensity of peaks cor-
responding to m/z of non-labeled and labeled FIBA,
CO3 and CO4 peptides were extracted and quantified.
2D LC-MS/MS identification of native serum peptides
Serum (200 μl) diluted with 600 μlo f8Mg u a n i d i n e
HCl was kept on ice for 5 min. The remaining steps
were as described above without spiking with the stan-
dard peptides. For each analysis, we combined two
ultrafiltrates. First dimensional HPLC separation was an
RP HPLC at pH 10.0. 200 mM NH4FA, pH 10, was
added to the ultrafiltrates to achieve a final concentra-
tion of 20 mM NH4FA. The diluted sample was loaded
onto an XTerra MS 3.5 μm C18 2.1 × 100 mm column.
T h et h e r m o s t a tw a ss e ta t4 0 ° Ca n dt h ef l o wr a t ea t0 . 2
ml/min. The peptides were eluted by a 2% to 62% B in
60 min formed by basic RP buffer A (20 mM NH4FA,
pH 10) and basic RP buffer B (90% AcN, 20 mM
NH4FA, pH 10). The chromatogram was monitored at
214 nm. Starting at 5 min, 14 fractions were collected
each 5 min. Peptides in each fraction were dried and re-
dissolved in 75 μl of LC-MS solvent A (2% AcN, 0.1%
FA) for an injection onto a nanoACQUITY system
(Waters, Milford, MA). Peptides were pre-concentrated
on a nanoACQUITY UPLC trapping column, 5 μm
Symmetry C18, 180 μm×2 0m ma taf l o wr a t e2 0μl/
min. The peptides were resolved on an analytical
nanoACQUITY UPLC column, 1.7 μm BEH C18,7 5μm
× 150 mm by a gradient formed by LC-MS solvents A
and B (98% AcN, 0.1% FA) at the flow rate 300 nl/min.
The linear gradient was from 2% to 40% B in 33 min
with on-line detection using a Q-TOF tandem mass
spectrometer (QSTAR Elite, Applied Biosystems/MDS
Sciex, Foster City, CA) equipped with a nanoelectros-
pray ion source with a PicoTip emitter. The instrument
was operated in the Information Dependent Acquisition
(IDA) mode in which the MS spectrum was recorded
for 1 s and the 4 strongest 2+, 3+, 4+ or 5+ ions were
selected for MS/MS with Dynamic Exclusion feature
enabled. The MS/MS spectra were recorded in the m/z
range 150 - 2000 using Automatic Collision Energy and
Automatic MS/MS Accumulation (max. accumulation
was 0.7 s). Each sample was injected twice.
The spectral data was searched using ProteinPilot 3.0
(Applied Biosystems/MDS Sciex, Foster City, CA) using
Lenco et al. Proteome Science 2012, 10:7
http://www.proteomesci.com/content/10/1/7
Page 9 of 12the Paragon algorithm, which uses a sequence-tag
search strategy, facilitating non-specific peptide identifi-
cation without inflating search times. The search was
specified using the following parameters in the Paragon
method: sample type - identification; cysteine alkylation
- none; digestion -none; instrument - QSTAR Elite ESI,
species - Homo sapiens; search effort - thorough. The
data were searched against the UniProt protein database.
The Proteomics System Performance Evaluation Pipeline
incorporated directly in ProteinPilot 3.0 was used to
conduct target/decoy searches facilitate initial FDR
estimates.
MS/MS spectral library
ProteinPilot results, including decoy hits, were output in
XML format using the vendor supplied tool, group2xml.
The resulting XML file was parsed using an in-house
script to permit filtering of the peptide identifications
for score and identified post-translational modifications;
to remove decoy hit peptides; and to permit re-estima-
tion of peptide, ion, and spectrum level FDR for the
remaining identifications. This script was used to elimi-
nate peptide identifications with identification confi-
dence (ProteinPilot Probability) less than 0.95; precursor
mass more than 0.2 Da from the theoretical monoisoto-
pic mass or the mass corresponding to the isotope clus-
ter peak associated with one, or two,
13C isotopes; and
modifications other than oxidation and Pyro-glu on Glu
and Gln. After filtering, the high-quality peptide identifi-
cations and their associated tandem mass-spectra, as
provided in the XML formatted output of ProteinPilot,
were reformatted as mzXML and pepXML, with corre-
sponding faux spectral identifiers. Skyline’s spectral
library (University of Washington, Seattle, WA) build
process reads the mzXML and pepXML file pair and
constructs a spectral library suitable for Skyline’sM R M
design tools. For each peptide ion (distinct peptide
sequence, charge and modification state), Skyline clus-
ters repeat identifications and selects a representative
spectrum that is, on average, most like the others in the
cluster. Only the representative spectra are retained.
After ProteinPilot analysis, 28,077 unfiltered peptide
identifications were formatted as XML, and 1469 were
retained by the above filters. After clustering, the spec-
tral library held MS/MS spectra for 416 peptide ions,
representing 349 native peptide sequences, for browsing
and MRM assay design. The library, configured for Sky-
line, facilitates the design of LC-MRM MS assays for
native peptides.
LC-MRM MS assays
Chromatographic separations were performed on a
nanoACQUITY system (Waters, Milford, MA). After
loading of the samples from a 4°C cooled autosampler,
peptides were pre-concentrated on a nanoACQUITY
UPLC trapping column, 5 μm Symmetry C18, 180 μm×
20 mm at a flow rate 15 μl/min for one min. Fast gradi-
ent from 20% to 45% of LC-MS solvent B in 5 min at a
flow rate 400 nl/min was used to resolve peptides on an
analytical nanoACQUITY UPLC column, 1.7 μmB E H
C18, 75 μm × 150 mm. Peptides were quantified on a
4000 QTRAP hybrid mass spectrometer (AB Sciex)
equipped with a nanoelectrospray ion source with a
PicoTip emitter. A spray voltage of 2400 V was used
with a source temperature 150°C. The mass spectro-
meter was operated in MRM mode with first quadru-
pole (Q1) filtering with 0.7 and third quadrupole (Q3)
filtering with 1.0 unit mass resolution. For all MRM
analyses, 30 ms dwell time was used for each transition.
MIDAS based enhanced product ion spectra were
recorded with Q1 filter set to 1.0 unit resolution.
Enhanced product ion spectra were recorded at a scan
speed 4000 amu/s between 150 to 1200 m/z,w i t h
enabled dynamic fill time and Q0 trapping.
The five most intense transitions for each suitable pre-
cursor were selected based on data deposited in the MS/
MS library using Skyline. LC-MRM MS chromatograms
were obtained on samples of native peptide from serum.
Detected peaks were subsequently validated by a
MIDAS experiment. After we unambiguously confirmed
the detectability of selected peptides in serum samples,
synthetic peptides were used for confirmatory analyses
and optimization of collision energy and declustering
potential. Three most intense optimized transitions per
precursor (FIBA and CO4) were used in the final
method for peptide quantification. The confirmatory
analyses of synthetic CO3 peptide revealed that the best
intensity transition is produced from its quadruply
charged ion. The final method for CO3 quantification
therefore included two most intense optimized transi-
tions from triply and quadruply charged precursors
which represent four most intense transition overall.
Carryover between injections as well as potential cross-
talk between light and heavy equivalents of the peptides
was subsequently examined. The final MRM method
was examined for the linearity of response and the limit
of quantification using relative dilution series experi-
ments (see Additional file 2). Potential background
interferences were assessed by comparing normalized
peak areas of each precursor to be monitored. The
values obtained from injections of heavy labeled pep-
tides dissolved in LC-MS solvent A were compared with
those originating from the spiked heavy labeled peptides
as well as from the native peptides in the serum sam-
ples. The MRM data were processed and evaluated in
Skyline.
Samples to be analyzed were prepared according to
the protocol described above. Sera (20 μl) were mixed
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gues for absolute quantification. To each microliter of
serum, 500 fmol of the FIBA and CO3 peptides and 50
f m o lo ft h eC O 4p e p t i d ew e r ea d d e dt o g e t h e rw i t h6 2 5
fmol of peptide SSKITHRIHWESASLLR per μlo f
serum, added to decrease non-specific adsorption of the
CO3 peptide. The amount of native peptides enriched
from an equivalent of 2 μl of original sera was injected
for the final analysis and each sample was measured in
duplicate. The MRM spectra data files were imported
into Skyline for evaluation. The quantity of the peptides
was determined by comparison to the spiked internal
standard. Data was exported to GraphPad Prism 5
(GraphPad Software, La Jolla, CA) for statistical
evaluation.
Additional material
Additional file 1: MSMS library.blib. Library of MS/MS spectra of serum
native peptides that can be readily imported into the Skyline software
for MRM transition design.
Additional file 2: Figure 1.pdf. Dilution curves for three native
peptides and the respective CV values (n = 3).
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